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It is well  understood  that  the  success  or failure  of a  mass  drug  administration  campaign  critically  depends
on  the  level  of  coverage  achieved.  To  that  end coverage  levels  are  often  closely  scrutinised  during  cam-
paigns  and  the  response  to  underperforming  campaigns  is  to  attempt  to improve  coverage.  Modelling
work  has  indicated,  however,  that  the quality  of  the  coverage  achieved  may  also  have  a  signiﬁcant  impact
on the  outcome.  If the  coverage  achieved  is  likely  to miss  similar  people  every  round  then  this  can  have
a  serious  detrimental  effect  on  the  campaign  outcome.  We  begin  by  reviewing  the  current  modelling
descriptions  of  this  effect  and  introduce  a  new  modelling  framework  that  can be used  to  simulate  a given
level  of  systematic  non-adherence.  We  formalise  the  likelihood  that people  may  miss  several  rounds  of
treatment  using  the  correlation  in  the  attendance  of  different  rounds.  Using  two  very  simpliﬁed  mod-
els  of  the  infection  of  helminths  and  non-helminths,  respectively,  we  demonstrate  that the  modelling
description  used  and  the  correlation  included  between  treatment  rounds  can  have  a profound  effect  on
the time  to elimination  of  disease  in  a population.  It is therefore  clear  that more  detailed  coverage  data
is required  to accurately  predict  the  time  to disease  elimination.  We  review  published  coverage  data  in
which  individuals  are  asked  how  many  previous  rounds  they  have  attended,  and  show  how  this  informa-
tion  may  be used  to  assess  the level  of  systematic  non-adherence.  We  note  that while  the coverages  in
the  data  found  range  from  40.5%  to 95.5%,  still  the correlations  found  lie  in  a fairly  narrow  range  (between
0.2806  and  0.5351).  This  indicates  that  the  level of  systematic  non-adherence  may  be similar  even  in  data
from  different  years,  countries,  diseases  and administered  drugs.
© 2017  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license. Background
Mass drug administration (MDA) is the cornerstone of a number
f control programs, particularly helminth control and trachoma
rograms, and also forms a part of the suite of interventions for
iseases such as malaria and yaws (World Health Organization,
013). These programs are based on the use of drugs with a good
afety proﬁle which can be distributed without close clinical super-
ision, and are usually prioritised because they are much more
ost-effective than screening and treating only infected individuals
ue to the logistic costs involved (Brooker et al., 2008; Holland et al.,
996). For neglected tropical diseases (NTDs), billions of individuals
∗ Corresponding author at: Mathematics Institute, University of Warwick, Coven-
ry,  UK.
E-mail address: l.dyson@warwick.ac.uk (L. Dyson).
ttp://dx.doi.org/10.1016/j.epidem.2017.02.002
755-4365/© 2017 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
have been treated in MDA  programs. In some of these programmes
key disease control goals have been met  so that MDA  could be
stopped (e.g. MDA  programmes for lymphatic ﬁlariasis in Egypt,
Yemen, Sri Lanka, etc. World Health Organization, 2015). However,
other programs are not achieving the expected goals, and so we are
facing the question of why these “failures” are occurring and how
better to measure the effectiveness of control programs.
Mathematical modelling plays an important role in the design
of MDA  programs—who to treat, when to treat (Anderson et al.,
2012, 2015; Coffeng et al., 2014, 2015; Gambhir and Pinsent,
2015; Gurarie et al., 2015; Irvine et al., 2015; Jambulingam et al.,
2016; Liu et al., 2015; Singh and Michael, 2015; Stolk et al., 2015;
Truscott et al., 2015; Winnen et al., 2002)—and in setting the
‘expected’ prevalence after a certain number of rounds, particu-
larly for onchocerciasis (Tekle et al., 2016). Modelling studies have
highlighted the importance of coverage (the proportion of the tar-
get population who are treated), with high coverage leading to
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ore rapid declines in prevalence and sustained high coverage
eading to the possibility of elimination (Okell et al., 2011; Slater
t al., 2014). Empirical studies (Krentel et al., 2013; Brieger et al.,
012; King et al., 2011; Boyd et al., 2010) have highlighted that
ome individuals do not receive treatment not through chance, but
hrough a systematic lack of access to the treatments (such as work-
rs who are away during the daytime treatments, Rock et al., 2015;
panya et al., 2012) or lack of acceptance of the treatment. These
tudies, among others, investigate how treatment campaigns and
nterventions are affected by the cultural and socio-economic con-
exts in which they occur (Krentel et al., 2016; Parker and Allen,
013a, 2013b; Roy et al., 2013; Shuford et al., 2016). In addition,
any investigations into treatment campaign coverage highlight
he unreliability of reported coverage data, further complicating
odelling efforts (Brieger et al., 2011; Cromwell et al., 2009).
Early modelling work for lymphatic ﬁlariasis highlighted how
hese types of systematic non-adherence to a program can under-
ine the success of that program and, depending on the size of the
ntreated group, act as an important reservoir for infection, lead-
ng to onward transmission to the rest of the population (Plaisier
t al., 2000). The decision to proceed with post treatment surveil-
ance may  be based on the reported coverage levels combined with
odelling predictions (for example in lymphatic ﬁlariasis, where
chieving around 7 years of high coverage is seen as a trigger to
egin transmission assessment surveys). It is important to measure
nd understand these effects to prevent the danger of stopping too
oon or continuing costly interventions after they are no longer
eeded. If untreated individuals are geographically clustered, then
his type of non-adherence, or lack of access, can lead to hotspots
f ongoing transmission. A more recent study applied the method
y Plaisier et al. (2000) (which was previously used in a determin-
stic setting) to study the effect of different models of systematic
on-adherence in an individual-based model of helminth infections
Farrell et al., 2017).
Different modelling groups have approached modelling system-
tic non-adherence (which we shall use as a catch-all term for the
ituation when some parts of the population repeatedly do not
eceive treatments) in different ways, but these different methods
ave never been explicitly compared with respect to the resulting
imulated coverage patterns or the resulting predicted trends in
nfection. Here we aim to formalise a new model for this behaviour
hich is ﬂexible enough to capture the different methodologies and
llow more direct comparison with empirical data. We  investigate
he impact of different assumptions for systematic non-adherence
sing a simple susceptible-infected-susceptible (SIS) model and
 helminth model. We  use examples from the small number of
ublished empirical studies which measure these phenomena to
valuate the size of the effect, and discuss the value of further sur-
eys to inform future modelling work. We  note that our work is an
ttempt to capture effects that may  be general across multiple dif-
erent diseases and to apply this to any particular disease or country
ould require more in-depth study of the speciﬁc situation.
. Overview
We  will begin by reviewing how various models include sys-
ematic non-adherence and introducing a new way  of modelling
reatment that allows the user to specify the level of systematic
on-adherence in addition to the coverage (Section 3). Then we
ill consider the consequences of systematic non-adherence in
DA  campaigns by implementing the various schemes into a (veryimpliﬁed) model of SIS dynamics and one for helminth infections,
emonstrating that the level of systematic non-adherence has a sig-
iﬁcant impact on the outcome of interventions (Section 4). Finally,
e will consider what data is required (and how to analyse it) tos 18 (2017) 56–66 57
assess the level of systematic non-adherence and will show that for
the limited data in the literature the correlation between rounds of
treatment lies in a narrow range of values (Section 5).
3. Modelling descriptions of systematic non-adherence
Many modelling descriptions of systematic non-adherence have
been used in a variety of models of different diseases. Here we
review and compare the different schemes and propose a new
method.
3.1. List of schemes
1. Random – each round a randomly selected group of individuals
are treated. (1 parameter – coverage)
2. Population partitioning:
(a) Fully systematic – two  groups that are treated: every round;
or never treated (1 parameter – coverage)
(b) Deterministic approximation to a semi-systematic scheme
(number of parameters depends on the scheme)
3. Semi-systematic – each individual has a probability pi (the same
for every round) of being treated in each round. (1 parameter –
coverage)
4. Variable correlation scheme – treated individuals are distributed
with a given expectation while correlation is controlled by a
given parameter. (2 parameters – coverage and correlation)
(a) Scheme by Grifﬁn et al. (2010) and Irvine et al. (2015)
(b) Controlled correlation scheme introduced in this paper
We discuss each scheme in detail below.
3.1.1. Random
The majority of modelling predictions for the outcome of mass
drug administration campaigns assume random coverage (Truscott
et al., 2015; Gambhir and Pinsent, 2015; Liu et al., 2015; Blok et al.,
2015; Pandey et al., 2015; Singh and Michael, 2015; Gurarie et al.,
2015; Anderson et al., 2015). In this scheme, each individual in each
round has the same probability, c, of receiving treatment, where c
is the coverage achieved by the campaign. If the campaign con-
tinues running for enough rounds then eventually all individuals
will have received at least one treatment. Since each individual has
the same probability of being treated in each round, the propor-
tion of the population that is never treated drops off very quickly
as the number of rounds increases. To ensure a probability of at
most T that a randomly selected individual has never received treat-
ment, at a given coverage c, requires greater than log(T)/log(1 − c)
rounds of MDA. The distribution of number of rounds attended in
the population after 10 rounds at 70% coverage is shown in Fig. 2(a),
demonstrating that the proportion of the population that have
never attended a round is very small. The distribution is clustered
around 7 rounds attended, since this would be the mean number of
rounds attended after 10 rounds at 70% coverage under this scheme.
3.1.2. Population partitioning
A simple way of incorporating systematic non-adherence into
any model (deterministic or individual-based) is to partition the
population into subpopulations that receive different treatment
regimes.
The most extreme version is a fully systematic scheme, where
every individual either attends every round, or never attends
any rounds. This scheme only requires knowledge of the cover-
age, which gives the proportion of the population that attends
every round. This scheme is most useful as a ‘worst case sce-
nario’. This scheme is implemented as one of multiple schemes
in a model for lymphatic ﬁlariasis (LYMFASIM: Stolk et al., 2008,
58 L. Dyson et al. / Epidemics 18 (2017) 56–66
Fig. 1. A schematic to represent the different schemes used to model treatment campaigns. For each scheme we give two rounds of treatment. Individuals receiving treatment
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eceive  treatment in that round, from white (never receive treatment) to dark blue
his  diagram but can give different levels of systematicness depending on the corre
003; Plaisier et al., 1998), and is also studied in a determinis-
ic model for onchocerciasis (Turner et al., 2015, 2014a,b). Plaisier
t al. (2000) assessed the comparative effectiveness of MDA  for
ymphatic ﬁlariasis with random, systematic or semi-systematic
overage schemes. The scheme is shown in Fig. 2(c).
Another partition would ﬁrst assume a subpopulation that never
ttends screening and then use another model of choice for the
emaining population. For example, incorporating a randomly-
articipating population and a never-participating population
HAT: Rock et al., 2015, hookworm: WORMSIM: Coffeng et al., 2015)
r a never-par-ticipating population and a semi-systematically
articipating population (see Section 3.1.3) (onchocerciasis:
NCHOSIM: Plaisier et al., 1990). To approximate a semi-systematic
cheme in a deterministic model, one can partition the population
nto groups that receive treatment at different rates. For example, a
DE model of onchocerciasis (EPIONCHO: Basá nez and Boussinesq,
999; Turner et al., 2013) the authors split the population into
our groups: one in which individuals participate every round; one
here they participate in even rounds; one participating in odd
ounds; and one group that never participates. This scheme is very
istinctive when we consider the number of rounds attended by
he different populations (Fig. 2(f)), and it would be very surprising
f this was seen in real data. However it is important to remem-
er that this scheme is not intended as a direct representation
f the real world, but as an attempt to make a semi-systematic
cheme in a deterministic setting. In addition, this scheme could
e extended by adding further subgroups that are treated every 1,
, 3, . . . rounds or indeed including a separate subpopulation for
ach possible combination of rounds attended.
.1.3. Semi-systematic
Under the semi-systematic scheme the ith individual has a
robability pi of attending a round of treatment. To achieve a cov-
rage c, each individual must have probability pi = u(1−c)/ci , where
i is a uniformly distributed random number on the interval [0,
]. Note that this scheme differs from the random scheme, since
he probability differs between individuals (but is the same forach diagram the background colour represents the probability that a person will
ys receive treatment). The controlled correlation scheme is not shown explicitly in
 parameter used.
each round), whereas in the random scheme the probability is
the same for all individuals (and is also the same for all rounds).
This can be extended to include sex- and age-related participa-
tion rates. The difference between the semi-systematic scheme
and the random scheme may  be easily seen in Fig. 2(b) where it
is clear that the semi-systematic scheme results in a larger pro-
portion of the population receiving zero or very few rounds of
treatment, even at 70% coverage levels, thus having the poten-
tial to seriously undermine MDA  campaigns. The semi-systematic
scheme has been considered in models of lymphatic ﬁlariasis (LYM-
FASIM: Jambulingam et al., 2016; Plaisier et al., 1998, 2000; Stolk
et al., 2003; Subramanian et al., 2004), hookworm (WORMSIM:
Coffeng et al., 2015), onchocerciasis (ONCHOSIM: Coffeng et al.,
2014; Plaisier et al., 1990; Stolk et al., 2015), and schistosomiasis
(SCHISTOSIM: de Vlas et al., 1996).
3.1.4. Variable correlation schemes
It is possible to ﬁt many of the preceding schemes into a general
framework in which the correlation between rounds attended (i.e.
if an individual attends one round to what extent they are more
likely to attend others) is set by the user in addition to setting the
coverage achieved. This was ﬁrst attempted by Grifﬁn et al. (2010)
and their scheme was subsequently used by Irvine et al. (2015)
(details in the supplementary information). However, while their
scheme gives a way  of increasing the correlation between rounds,
it does not allow the user to directly set the correlation exactly.
In addition, there is no way  of reproducing the semi-systematic
scheme described above, since higher correlations are achieved by
including a larger number of people that always or never attend
treatment (see Fig. 2(d) and (e)).
We propose a new scheme (using a method by Qaqish, 2003) in
which both the coverage, c, and the correlation between rounds, ,
may  be controlled exactly. We  call this scheme the controlled cor-
relation scheme. The procedure is as follows: in the ﬁrst round, each
person attends treatment with probability c. In round k, individual
i attends treatment with probability (c(1 − ) + Ri)/(1 + (k − 2)),
where Ri is the number of rounds attended by person i so far. It is
clear that the more rounds a person has previously attended, the
L. Dyson et al. / Epidemics 18 (2017) 56–66 59
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ore likely they are to attend subsequent rounds, and the strength
f this effect is controlled by . If  = 0 then this reduces to the
andom scheme (Section 3.1.1, Fig. 2(a) and (g)), and if  = 1 then
ach person will attend round k if, and only if, they attended the
rst round, thus reducing to the systematic scheme in Section 3.1.2
Fig. 2(c) and (i)). In fact this scheme is equivalent to giving each per-
on a parameter that gives their probability of attending any round
which is ﬁxed for that person), as in the semi-systematic scheme,
ut drawing that parameter from a Beta distribution with param-
ters  ˛ = y(1 − )/) and  ˇ = (1 − y)(1 − )/ (see supplementary
nformation).
As for previous schemes, the variable correlation scheme may  be
traightforwardly applied to subpopulations with different atten-
ance parameters (for example different age groups) by generating
ttendances separately for each subpopulation. It is also possible
o extend this scheme (see supplementary information) to include
dditional correlated variables to model correlations between
dherence to different types of interventions or between risk and
dherence to interventions. For example, it might be that people
ho are likely to receive drug treatments are also more likely toced by the population for different schemes at 70% coverage.
receive indoor residual spraying (IRS) or to receive and use bednets
(Grifﬁn et al., 2010).
4. What are the consequences of systematic
non-adherence?
To assess the impact of the schemes discussed in Section 3.1,
we use two  very simpliﬁed models of infection dynamics: an ‘SIS’
model; and a simpliﬁed helminth infection model, before brieﬂy
considering the effect of correlations between treatment and infec-
tion risk.
4.1. SIS dynamics
In our SIS model individuals are either infected (I) or suscepti-
ble (S), and infecteds infect susceptibles at a rate,  ˇ and recover at
a rate  . We simulate the system stochastically using the Gillespie
algorithm (Gillespie, 1977). In addition, we include mass treatment
events using the schemes in Section 3.1. We consider two differ-
ent model outputs: the prevalence of infection over time; and the
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revalence of infection after 5 years. For each prevalence measure,
e give the prevalence scaled by the prevalence achieved by most
ffective scheme: a fully random treatment campaign. For example,
n Fig. 3(a) we see that the prevalence after 5 years can be up to 180
imes greater for a systematic scheme than for random coverage.
.1.1. Impact of the intervention
We run the model to steady state (200 years, giving a starting
revalence of 0.08 for  ˇ = 0.2 and 0.25 for  ˇ = 0.8) before beginning
he plotted simulations with a mass drug treatment at year zero.
ode for the simulations may  be found as supplementary infor-
ation. At the second round the different schemes will have a
ifferent level of overlap with previously cured individuals. The
ore ‘systematic’ schemes will tend to re-treat individuals who
ere previously treated at time zero, so that this will only decrease
he prevalence if those individuals have since been reinfected. Over
epeated treatments, the difference between the more and less sys-
ematic schemes becomes progressively greater (Fig. 3 (a) and (b)).
arying the coverage levels and considering the prevalence after 5
ears demonstrates that the effect of systematic non-adherence is
reater at higher coverages
We  may  also investigate different endemic settings, in which
nfection happens at different rates. Systematic non-adherence has
 much greater effect when infection rates are slower (Fig. 3(a) and
b)), since at lower infection rates the individuals that are repeat-
dly treated in the more systematic schemes are unlikely to have
ecome reinfected between treatments. At the extreme, if the infec-
ion rate is so high that all individuals are reinfected by the end of
 year, it is clear that the different schemes would have exactly the
ame impact, since the coverage is the same in all the schemes.
.1.2. Prevalence after 5 years
To investigate more how the different schemes vary with cover-
ge rates, we consider the prevalence after 5 years for varying levels
f coverage and different infection rates (Fig. 3(c) and (d)). These ﬁg-
res display an even more clear distinction between the different
chemes, with more systematic schemes displaying huge differ-
nces in prevalences. The effect of systematic non-adherence is
ore pronounced at higher coverages, since the difference between
he populations treated is greater when more people are being
reated in general. At very high coverages the less systematic
chemes can eliminate the disease from the population, and for this
eason we do not give data for greater than 70% coverage (since we
cale by the prevalence from the random scheme, which is often
ero after 5 years at high coverages).
.2. Helminth dynamics
The impact of systematically re-treating individuals is less clear
n a model of helminth infections, since individuals are not regarded
o be simply infected or susceptible. Instead they are infected with
 number of worms (which may  be zero). In this model the preva-
ence of the disease in the population is given by the proportion of
he population that have a non-zero number of worms. When indi-
iduals are treated they are not necessarily fully cured, but instead
 proportion of their worms are killed. In these models, therefore,
ndividuals that are treated multiple times are more likely to be
ured than those that only receive one treatment. Hence it is pos-
ible that a degree of ’systematicness’ could reduce the prevalence
n the population, particularly at low coverages, by concentrating
hose treatments so that a lower subpopulation is treated, but they
re more likely to be fully cured.We  again take a very simpliﬁed model to highlight the differ-
nces in the treatment schemes without including much detail
bout the infection dynamics. In particular, we are not modelling
ny particular type of helminth, and the parameters we  use ares 18 (2017) 56–66
not informed by real world data. We  do not include any details of
worm replication which in reality, depending on the species, can
be sexual or asexual, and we  only consider adult worms, neglect-
ing larvae stages and vectors of infection, such as insects or snails.
Instead we  use a model in which individuals are infected with a
number of worms, which die at a rate  . An individual i gains worms
increase through contact with another infected individual, j, at a
rate (ˇ
∑
jWj/N)C/(C + Wi), where  ˇ is the infectivity, N is the popu-
lation size and C gives density dependence, so that as the number of
worms in a single individual increases, the ‘space’ for new worms
decreases. We  also include death of the individual, which is paired
with new births so that the net effect of a person dying is that they
are replaced by a completely uninfected person.
4.2.1. Plotting the prevalence during a mass drug campaign
As before we  plot the prevalence in the population over time
during a mass drug campaign, scaled by that attained by a random
coverage model. We  run the model to steady state (200 years, giv-
ing a starting prevalence of 0.15 for  ˇ = 0.2 and 0.25 for  ˇ = 0.25)
before administering a treatment round at time = 0 years (Fig. 4).
Code for the simulations may  be found as supplementary informa-
tion. We  previously mentioned the possibility that concentrating
treatments in a subpopulation may  lead to a lower prevalence (i.e.
proportion of the population that is infected) while still increas-
ing the average number of worms. We  note here, however, that
this is never observed in our model simulations. An increase in
‘systematicness’ always leads to higher prevalences in our model
simulations (Fig. 4), as was  observed in the SIS system. As in the SIS
model, the effect of systematic non-adherence is more pronounced
at low infection rates (Fig. 4(a) and (c)). We note that the effect
is somewhat reduced compared to the SIS model with systematic
treatment producing prevalences up to 70 times that for random
treatment in the helminth model, compared to 180 times in the SIS
model. However this may  be inﬂuenced by the parameter values
chosen.
4.3. Correlations between treatment and infection risk
Another type of systematic effect that can have a large inﬂuence
on the system dynamics is a correlation between adherence and
infection risk. In this situation individuals that are unlikely to be
treated also have a higher risk of being infected. We would expect
this to have negative consequences for a treatment campaign, since
the population that is most likely to be infected is also the least
likely to be treated for that infection.
We  may  study this using a very simple model, in which each
individual i has some probability Ti of receiving treatment, and
acquires disease at some rate ˇi, then their probability Pi(t) of being
infected at time t is given by
dPi
dt
= ˇi(1 − Pi) − TiPi, (1)
Pi(Ti, ˇi, t) =
ˇi + Tie−t(Ti+ˇi)
ˇi + Ti
. (2)
We ﬁnd by studying this system (see supplementary information)
that a positive correlation between treatment and infection is likely
to initially increase prevalence compared to a situation without
such a correlation. This can be intuitively understood, since at the
beginning of a treatment campaign it is better to focus on the ‘easy
gains’ by treating those people that will not quickly become rein-
fected. This effect is seen in simulations of our SIS and helminth
models incorporating correlations between infection risk and treat-
ment (see supplementary information).
L. Dyson et al. / Epidemics 18 (2017) 56–66 61
Fig. 3. The impact of different types mass drug administration coverage on: (a) and (b) the prevalence; (c) and (d) the prevalence after 5 years; of an SIS model over multiple
rounds  of treatment, for different infection rates,  ˇ when using a coverage of 70%. In each plot the schemes we expect to have high systematic non-coverage are shown in
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sed,  those that are more random are in blue, and those with some systematicness 
imulations and are scaled by the prevalence attained when using the random cove
 = 0.2 and of 0.03 for  ˇ = 0.25.
. Using data to assess the extent of systematic
on-adherence
The preceding sections have demonstrated the impact of sys-
ematic non-adherence on the prevalence of disease. In addition,
he form of the non-adherence also has an impact on elimination
ime and disease burden over time. While the coverage is gener-
lly acknowledged to have a fundamental impact on the success
f a campaign, the form that coverage might take is less widely
tudied. For this reason good quality data on the level and form of
on-adherence is relatively sparse. It is important to note, how-
ver, that even if the coverage and correlations are known, this
oes not fully specify the distribution of attendance. In spite of
his, we will argue that data about non-adherence should be rou-
inely collected during a mass drug administration campaign, in the
ame way that data about coverage is commonly taken and stud-
ed. This would represent a signiﬁcant step forward in quantifying
ystematic non-adherence.own in green. We take the rate of recovery,  = 0.15. Lines are averaged over 1000
cheme. For reference, the random coverage scheme attains a prevalence 0.0003 for
5.1. Existing data
For helminth infections, a systematic review was undertaken by
Shuford et al. (2016). Many of the studies included in this review
reported coverage data, or were investigations into the reasons for
non-compliance. These papers give insight into factors associated
with non-compliance, but not the extent to which an individual is
likely to receive multiple rounds of treatment. Discovering the rea-
sons for non-compliance is invaluable when attempting to increase
coverage, but for modelling purposes a more simple measure of
the level of correlation between treatment rounds would signiﬁ-
cantly increase the accuracy of predictions. Some published articles
(King et al., 2011; Brieger et al., 2012) hint at access to data that
would give this information, but correlation measures are not gen-
erally calculated or published. A few articles do include data of the
form plotted in Fig. 2 (Newell, 1997; Plaisier et al., 2000; Brieger
et al., 2011; Mathieu et al., 2006; El-Setouhy et al., 2007). Notably
Plaisier et al. (2000) also include a comparison of the distribution of
rounds attended against random, systematic and semi-systematic
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Fig. 4. The impact of different types mass drug administration coverage on: (a) and (b) the prevalence; (c) and (d) the prevalence after 5 years; of a simpliﬁed helminth model
over  multiple rounds of treatment, for different infection rates,  ˇ when using a coverage of 70%. In each plot the schemes we  expect to have high systematic non-coverage
are  shown in red, those that are more random are in blue, and those with some systematicness are shown in green. We  take the rate of death of worms to be  = 0.1, the
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airth/death rate of people to be 0.1, the density dependence parameter to be C = 5
ver  1000 simulations and are scaled by the prevalence attained when using the ra
.0005 for  ˇ = 0.2 and of 0.016 for  ˇ = 0.8.
ttendance, and conclude that semi-systematic attendance is the
ost realistic of the three schemes. Since numerical data is not
iven in Plaisier et al. (2000), we will consider only Newell (1997),
rieger et al. (2011), Mathieu et al. (2006) and El-Setouhy et al.
2007). Both Brieger et al. (2011) and Newell (1997) investigate
reatment for onchocerciasis with ivermectin. Newell (1997) report
 rounds of treatment in Burundi, while Brieger et al. (2011) inves-
igate the African Programme for Onchocerciasis Control (APOC),
tudying projects in Nigeria and Cameroon. Mathieu et al. (2006)
nd El-Setouhy et al. (2007) examine participation in mass drug
dministration of lymphatic ﬁlariasis with DEC and albendazole in
eogane, Haiti and Egypt, respectively.
.2. Data analysisOnly Mathieu et al. (2006) gives the numbers attending all differ-
nt combinations of rounds (e.g. the percentage of the population
ttending only rounds 1 and 2, say). From the combinations of assume that each treatment kills 70% of that person’s worms. Lines are averaged
coverage scheme. For reference, the random coverage scheme attains a prevalence
rounds in Mathieu et al. (2006) it is straightforward to calculate
the coverages of different rounds (round 1 = 60%, round 2 = 62%
and round 3 = 68%) and the correlations between different rounds
(corr12 = 0.5351, corr13 = 0.2979 and corr23 = 0.5247).
However it is also possible to use the distribution of number of
rounds attended, by making the assumption that all rounds are sim-
ilar. This is a simplifying assumption, that is not generally entirely
satisﬁed, but gives an indication of the required correlations. To use
the distribution of number of rounds attended, we  deﬁne Xi to be
a vector of length given by the population size, which is one if that
individual attended the drug administration in round i, and zero
otherwise. Then Z =
∑
iXi gives how many rounds each individual
attended. We  wish to know the correlations corr(Xi, Xj) for i /= j. To
determine this we use the relationship:var
(∑
i
Xi
)
=
∑
i
var(Xi) + 2
∑
i
i∑
j=1
cov(Xi, Xj). (3)
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wFig. 5. Existing data (blue bars) with controlled correlation scheme
ence if the Xi are identically distributed then var(Xi) = var(X) for
ll i and cov(Xi1 , Xj1 ) = cov(Xi2 , Xj2 ) for all i1, j1, i2, j2, and
orr(Xi, Xj) =
cov(Xi, Xj)
var(X)
, (4)
var(Z)
M(M + 1)var(X) −
1
M + 1 , (5)
here M is the number of rounds. We  may  also calculate var(X)
rom Z via the formula
(Z) = E
(∑
Xi
)
=
∑
E(Xi), (6)
ence
(X) = 1
M
E(Z), (7)
nd, since X is a Bernoulli random variable with mean E(X), then
ar(X) = E(X)(1 − E(X)). For each dataset we  calculate the esti-
ated coverage per year and estimated correlation. We  plot the
ata (blue bars in Fig. 5) along with distribution obtained by using
hese with the controlled correlation scheme (red lines in Fig. 5).
Applying this to the data in Mathieu et al. (2006) we  obtain an
stimated coverage per year of 66% and an estimated correlation
f 0.4152 between years. This seems like a reasonable estimate
f both the coverages and the correlations, while clearly not cap-
uring the lower correlation between rounds 1 and 3 seen in the
ndividual-level data. This limitation can also be seen when plot-
ing the distributions (Fig. 5) since the low proportion attending
xactly one round is not well captured.
Both Brieger et al. (2011) and Newell (1997) give only the num-
er of rounds attended. Using our technique on the data from
ewell (1997) gives an estimated coverage of 60% and a correlation
f 0.3268, contrasting with reported coverages of between 40.5%
nd 49.0% (Newell, 1997). However, the ﬁt obtained by using the
stimated coverage and correlation is good, only showing a small
verestimate for the percentage attending one round (Fig. 5(b)).
rieger et al. (2011) present a larger number of treatment rounds
Fig. 5(c)), from which we estimate a coverage of 57% and a corre-
ation of 0.3108. This dataset highlights the issue of assuming all
ounds are approximately the same, since we would expect cov-
rages to vary over the large number of rounds. Mean coverage
ates were only reported for three years: 70% in 2003; 70% in 2004
nd 74% in 2005 (Brieger et al., 2011). Given these drawbacks it is
erhaps surprising that this dataset seems to show the best ﬁt so
ar (Fig. 5(c)). This may  be due to the larger amount of data that
an be ﬁt and the smaller impact of the ﬂuctuations in individual
ears on the overall ﬁt. In addition, the attendances in this dataset
ere taken from village registers to avoid reporting bias, which maybutions using the estimated correlations and coverages (red lines).
improve the quality of the dataset, while also indicating that more
detailed individual-level data may  be available. The discrepancies
found by Brieger et al. (2011) between the village registers and the
reported coverage levels is indicative of the need to examine the
accuracy of coverage reporting and assessment.
Finally, El-Setouhy et al. (2007) reported the number of rounds
attended (assessed by a sample survey) after each round of MDA  up
to a total of 5 (Fig. 6). This gives us the opportunity to calculate our
statistical measures over multiple rounds, testing the assumption
that the different rounds are roughly the same. The mean cover-
ages found after each year were 82.41%, 88.24%, 83.74%, 69.26% and
74.51%, which were a little lower than those reported (86.7%, 95.5%,
90.1% and 88.8% for rounds 1–4, while coverage was  not reported
for round 5). Note that the two values are not exactly comparable
for each round since, for example, in round 4, the mean cover-
age is averaged over rounds 1–4, whereas the reported coverage
is just for that year. It should also be noted that, since the peo-
ple surveyed were different after each round, the reported data is
in fact inconsistent, with the percentage of people receiving zero
rounds of treatment increasing over time. The estimated average
correlation between rounds was  found (using equation (5)) to be
0.2806, 0.3957, 0.3446 and 0.4467 after rounds 2, 3, 4 and 5, respec-
tively. This would imply that the level of systematic noncompliance
increases over time, which is somewhat intuitive: one might expect
that after multiple rounds of MDA  people get into the habit of
attending or not attending.
The range of values taken by the data is shown in Fig. 7 with cal-
culated average coverages and correlations (coloured circles) and
reported coverages (coloured triangles). We can see from this that
our calculated coverages can be systematically higher or lower than
the reported coverages but, with the exception of the El-Setouhy
et al. (2007) data, are not a large deviation. In addition, while the
coverages in our data range from 40.5% to 95.5%, the range of cor-
relations found is quite narrow (between 0.2806 and 0.5351). Thus
there is some evidence that correlations may  be approximately the
same, even in data from different years, countries, diseases and
administered drugs. We  show the distribution of number of rounds
attended for our controlled correlation model with correlation 0.4
in Fig. 2(h) for comparison with the other schemes.
6. Discussion
Systematic non-adherence is clearly an important factor in the
success or failure of an MDA  campaign, but it’s impact depends
on the extent of the permanent or occasional lack of treatment for
these groups, and the size of those groups. Therefore, the conclu-
sions of modelling studies depend importantly on the underlying
assumptions about this behaviour. Here we have summarised the
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dig. 6. Data (blue bars) from El-Setouhy et al., 2007 with controlled correlation sch
he  estimated correlation from all the rounds (red stars).
ifferent ways of modelling systematic non-adherence, showing
he range of different assumptions that have been made in the
odelling literature. Individual-based modellers were the ﬁrst to
ntroduce systematic non-adherence, making use of their model’s
exibility in characterising individual behaviours (Plaisier et al.,
990, 1998; de Vlas et al., 1996). More recently, compartmen-
al, deterministic models have been adapted to use a variety of
ethodologies for representing this behaviour, each of which have
articular limitations (Basá nez and Boussinesq, 1999; Turner et al.,
013). Here we have introduced a new, more ﬂexible way of includ-
ng this effect in mathematical models. Our proposed variable
orrelation scheme allows the explicit inclusion of a correlation
etween rounds, but the scheme as proposed requires the coverage
evels to remain the same over multiple rounds and the correlations
etween any two rounds to be the same. We  note that the scheme
ay  easily be extended using techniques by Qaqish (2003) to pro-
uce speciﬁed coverage levels and/or a speciﬁed correlation matrix
etween rounds.
Using simpliﬁed models of infection, we investigated the impact
f different assumptions on infection rates, coverage and system-
tic non-adherence and conclude that the effect of systematic
on-adherence is more extreme at lower rates of infection. It
ppears that the effects are slightly lower in helminth models com-
ared to the SIS model, however this may  be due to the parameter
alues chosen. We note that more complicated models of helminth
ynamics, in which different assumptions are taken for each spe-istributions using the estimated correlation up to that round (red lines) and using
ciﬁc helminth species may  affect this result. More work is needed
to fully understand how the impact of treatments on the proba-
bility of disease transmission may  change the effects of systematic
non-adherence.
In the case where non-adherence to treatment is correlated
with infection risk, such as in sub-populations with poor sanita-
tion and poor access to health-care, then this generally leads to
higher prevalences in the long run. However in this situation, sur-
prisingly, it is better to focus on treating people who are not at
risk of infection early in the program, since they are more likely to
remain uninfected after being cured.
Although there are only a few studies characterising the extent
of systematic non-adherence, we  have demonstrated that gather-
ing data about the number of rounds that people attend can be
used to determine the correlation between years, which is needed
to parameterise models of systematic non-adherence. Despite our
(small amount of) data coming from different sources, types of
infections, years and countries, the parameter values we obtain are
relatively similar (with correlations between 0.28 and 0.54). More
data of this type needs to be collected to dramatically increase the
accuracy of our predictions. While there are concerns about the
quality of data achievable (particularly the ability of individuals
to accurately report the number of rounds of treatment they have
received, Brieger et al., 2011; Shuford et al., 2016), even small addi-
tional information could be potentially useful and the collection of
such data should be informed by the local context. Whilst we focus
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Fig. 7. An overview of the datasets obtained with calculated average coverages and
correlations (coloured circles) and reported coverages (coloured triangles). For the
El-Setouhy et al. (2007) dataset the colours refer to the round that the data is taken
from, so that the triangles give the reported coverage for rounds 1–4, while the cir-
cles  represent the calculated average coverages and correlations after 2–5 rounds.
The horizontal lines demonstrate which reported coverages refer to which calcu-
lated values, while the vertical line for Mathieu et al. (2006) shows the range of
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individual compliance with mass drug administration for elimination oforrelations found when using the full dataset (which reports which rounds people
ttended, rather than just how many rounds).
n a general description, it is important to identify and quantify the
ocial and logistical drivers in order to overcome them. It is impor-
ant to note that correlations in different geographical areas may
e a way of prediction where hotspots are most likely to occur.
. Conclusions
Overall this study highlights the importance of careful
onsideration of the drivers and characteristics of systematic non-
dherence, and of model comparison, so that different predictions
an be evaluated in terms of their parameter and structural assump-
ions. Further work should focus in two main areas: gathering
ata and extending analytical tools to quantify the extent of sys-
ematic non-adherence; and expanding current and future models
o include and analyse these effects. We  do not make claims for
ny particular diseases in this work, but instead demonstrate that
ystematic non-adherence can have a large effect and encour-
ge others to investigate these effects in their own disease- and
ountry-speciﬁc circumstances.
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